FDA grants fast track status to SRF388 for hepatocellular carcinoma

The FDA granted fast track designation to SRF388 for treatment of certain patients with hepatocellular carcinoma, according to the agent’s manufacturer.The designation applies to use of SRF388 (Surface Oncology) by patients previously treated with standard therapies, such as VEGF-targeted agents and PD-L1 blockade.“Liver cancer is the most rapidly increasing type of cancer in both men and women in the U.S., with incidences tripling since 1980,” Rob Ross, MD, chief medical officer of Surface Oncology, said in a company-issued press release. “There is a significant needRead More

Share on facebook
Share on twitter
Share on linkedin